16 August 2021 | News
To discuss key learnings and takeaways in the clinical trial and regulatory space across the Asia region
This first DIA transnational conference will provide a holistic view on the clinical trial and regulatory space post-COVID evolution
DIA announced that the 2021 Asia Meeting will be held virtually on September 7 from 8:45 AM to 5:00 PM (Singapore Standard Time).
Conference topics include: Bio-Venture / Mega-Pharma Building Ecosystems in Asia, MRCT During and Post-COVID, Digital Technology Advancing the Modernization of Regulatory Science & Drug Development, and Real-World Evidence.
Fostering solutions in a multi-stakeholder, neutral forum
The COVID-19 outbreak brought unprecedented changes to the way we live and work, especially in the R&D field. DIA Asia 2021 will be the first transnational post-COVID conference connecting industry experts and regulators to discuss key learnings and takeaways in the clinical trial and regulatory space across the Asia region.
According to Shun Jin, Head Regulatory Affairs at Sandoz and Programme Chair, “Regulatory convergence is always a hot topic. Especially with the recent global political environment change, how would such political environment change impact the healthcare policy convergence? We will especially focus on the difference between Asia countries and Westerner countries on vaccines, control, testing, and more.”
Building innovative and sustainable ecosystems
The growth potential of Asian pharmaceutical and life science industries is astounding over the past few years. Despite Asia being a collection of markets with very diverse sets of regulatory environments, demographics, economic impact, and disease profiles, the regional ecosystem is investing in its capabilities to advance patient centricity in the healthcare and life science sector.
Jing Ping Yeo, Consultant – Clinical, sees the conference as a unique forum to get a real understanding about the special structure of the region, as “The audience has the opportunities to hear directly from the relevant stakeholders and also to sense the Asian environment directly.”
Real-world evidence fundamentally changes healthcare
With RWE, collecting and utilizing data from clinical practices, from robust electronic health records, or from settings that reflect the reality of day-to-day healthcare delivery, becomes increasingly important in the approval process. This will broaden the development of drugs and ensures a better understanding of patient population risks and benefits. To discuss these opportunities, DIA Asia 2021 gathers leading experts sharing their insights on the current status, best practices and examples.
Exclusive Line-Up of Speakers
DIA Asia 2021 gathers leading experts including: Danny Soon, Chief Executive Officer Consortium for Clinical Research and Innovation, Singapore, & Executive Director at Singapore Clinical Research Institute, who will review how the bioventures, mega pharmas and small startups collaborate with governments and regulators to build an innovative and sustainable ecosystem.
Takahiro Nonaka, Head of Epidemiology Medical information Division (PMDA), and Kinwei Chan, Professor and Director at National Taiwan University Hospital, who will talk about how Real-World Evidence (RWE) is changing the landscape of drug development, clinical trials and regulatory decision-making processes through the entire healthcare chain.
Tong Guo, Executive Vice President LinkDoc Technology, and Kai Langel, Senior Director Strategy and Innovation Global Regulatory Policy at Janssen, will discuss how updated digital technology can advance the regulatory system modernization.
Registration for this virtual event is opened and Early Bird rates are available until August 21. Event website: https://bit.ly/3slaRqW